You will be shown an abstract from a biomedical research paper. Given this abstract, your task is to extract all unique entities of the following types: ["Outcome", "Participant", "Intervention"].

Please return the output as a JSON object of the format: {"Participant" : ["patients with COPD", ...], "Intervention" : ["Atenolol", ...], "Outcome" : ["blood pressure", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders . The targeted mechanism of factor Xa inhibition has been studied extensively , initially as prophylaxis for venous thromboembolism ( VTE ) in the orthopedic surgical setting . Future therapeutic directions for selective factor Xa inhibition in the management of other thrombotic diseases are discussed . Thromboembolic diseases can occur in the venous or arterial sides of the circulatory system . Factor Xa inhibition is a targeted approach to anticoagulation that resulted from significant advances in our understanding of the coagulation cascade . The factor Xa inhibitor fondaparinux has been studied extensively in the orthopedic surgical setting for the prophylaxis of VTE . Current investigations that are under way or completed evaluate the efficacy and safety of fondaparinux for the management of various thrombotic diseases . The future development of fondaparinux resides primarily in three therapeutic areas : prevention of VTE , treatment of VTE , and treatment of acute coronary syndromes . For the prevention of VTE , fondaparinux has been studied as extended prophylaxis following hip fracture surgery ( PENTHIFRA Plus ) , for use in high-risk abdominal surgical patients ( PEGASUS and APOLLO ) , and for use in medical patients ( ARTEMIS ) . Studies evaluating fondaparinux for the treatment of VTE are part of the large MATISSE clinical program ( MATISSE DVT and MATISSE PE ) . Fondaparinux was investigated in phase 2 studies for the treatment of acute coronary syndromes , including acute ST-segment myocardial infarction ( PENTALYSE ) and unstable angina ( PENTUA ) . Encouraging data from these trials are the basis for phase 3 programs in this area ( MICHELANGELO ) . The orthopedic prophylactic and nonorthopedic clinical programs for fondaparinux in the management of thrombosis support the concept that targeted inhibition of coagulation is an effective advance in antithrombotic therapy .
{"Intervention": ["fondaparinux", "factor Xa inhibitor fondaparinux", "Fondaparinux"], "Outcome": ["targeted inhibition of coagulation", "acute coronary syndromes", "acute ST-segment myocardial infarction ( PENTALYSE ) and unstable angina ( PENTUA )", "efficacy and safety"], "Participant": ["venous thromboembolism ( VTE )", "acute coronary syndromes", "thrombotic disorders ."]}